PHETA2

Across TCGA pan-cancer cohorts, PHETA2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PHETA2 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PHETA2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PHETA2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where PHETA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	1.000	0.800	.004	25	view →
LSCC	DFS	Median	III,IV	0.410	0.876	.002	13	view →
UCEC	DFS	Median	II,III,IV	0.273	1.000	.002	12	view →
LUAD	OS	Median	All	1.000	0.694	.015	4	view →
GBM	DFS	Median	All	0.580	0.247	.018	3	view →
HNSC	DFS	Median	IV	0.920	1.000	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PHETA2–PDAC (OS)

Open the PDAC breakdown →